Physician profile
April Weber
NPI 1073092979
$2,609.62
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $1,174 · 2023: $1,068 · 2024: $24.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $474.76 | 2021-2023 | Breztri, Farxiga, Fasenra |
| Novo Nordisk INC | $408.88 | 2021-2023 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $401.10 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Abbvie INC. | $257.40 | 2021-2023 | |
| Glaxosmithkline, LLC. | $172.90 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.38 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $130.29 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $125.00 | 2021 | |
| Amgen INC. | $67.08 | 2022-2023 | Evenity, Prolia |
| Dexcom, INC. | $57.65 | 2022-2024 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $57.03 | 2022-2023 | Linzess |
| Biohaven Pharmaceutical Holding Company LTD. | $55.13 | 2022 | |
| Astellas Pharma US INC | $39.64 | 2022-2023 | Myrbetriq, Veozah |
| Pfizer INC. | $39.46 | 2023 | |
| Exact Sciences Corporation | $30.34 | 2023 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $29.50 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.02 | 2021-2023 | Trintellix |
| Sanofi Pasteur INC. | $22.47 | 2022 | |
| Merck Sharp & Dohme LLC | $17.00 | 2023 | Steglatro, Steglujan, Belsomra |
| Cranial Technologies, INC | $16.14 | 2023 | Doc Band |
| Biohaven Pharmaceuticals, INC. | $15.54 | 2021 | |
| Lundbeck LLC | $14.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.